Anzeige
Mehr »
Lynx Broker
Login
Dienstag, 22.10.2019 Börsentäglich über 12.000 News von 614 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PLYX ISIN: US47010C4096 Ticker-Symbol: 1JA2 
Tradegate
18.10.19
18:39 Uhr
0,660 Euro
0,000
0,00 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
JAGUAR HEALTH INC Chart 1 Jahr
5-Tage-Chart
JAGUAR HEALTH INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,651
0,664
21.10.
0,630
0,665
21.10.

Aktuelle News zur JAGUAR HEALTH Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
10.10.Jaguar Health to explore license deals for Mytesi in China5
10.10.Jaguar Health, Inc.: Jaguar Health Engages Firm to Explore Potential License Agreements and Collaborations for Mytesi in China303Jaguar Health Receives $1.75 Million in Proceeds from Warrant Exercise at an Exercise Price of $1.40 SAN FRANCISCO, CA / ACCESSWIRE / October 10, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar"...
► Artikel lesen
04.10.Jaguar Health, Inc.: Jaguar Health Eliminates Certain Royalty Obligations Reducing Future COGS for Mytesi and Crofelemer312SAN FRANCISCO, CA / ACCESSWIRE / October 4, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that a License Termination and Settlement agreement ("LTSA") related...
► Artikel lesen
JAGUAR HEALTH Aktien jetzt im kostenlosen Demokonto handeln!
03.10.Jaguar Health, Inc. - 8-K, Current Report6
01.10.Jaguar Health files final Canalevia technical section for CID in dogs5
01.10.Jaguar Health, Inc.: Jaguar Health Files Final Canalevia (Crofelemer) Technical Section for Proposed Indication of Chemotherapy-Induced Diarrhea in Dogs250Reminder: Company to Host Investor Call October 3rd at 8 a.m. Eastern to Provide Updates Regarding Development of Mytesi® (Crofelemer) for the Potential Follow-on Indication of Cancer Therapy-Related...
► Artikel lesen
30.09.Jaguar Health, Inc.: Jaguar Health Subsidiary Receives Notice of Allowance from Canadian Intellectual Property Office for Patent Application210SAN FRANCISCO, CA / ACCESSWIRE / September 30, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that the Company's wholly-owned, human-health focused subsidiary...
► Artikel lesen
28.09.Jaguar Health -4.2% on holder offering up to 2.8M shares4
27.09.Jaguar Health, Inc. - S-1, General form for registration of securities3
26.09.Jaguar Health, Inc.: Jaguar Health Subsidiary Napo Pharmaceuticals to Host Facebook Live "HIV Community Conversation" Event with HIV Advocate Mark S. King September 27, 2019 at 3 p.m. Eastern299SAN FRANCISCO, CA / ACCESSWIRE / September 26, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"), today announced that the Company's wholly-owned, human-health focused subsidiary...
► Artikel lesen
25.09.Jaguar Health down 14% ahead of Mytesi update4
24.09.Jaguar Health, Inc.: Jaguar Health to Host Investor Call October 3rd at 8 a.m. Eastern to Provide Updates Regarding Development of Mytesi for the Potential Follow-on Indication of Cancer Therapy-Related Diarrhea200SAN FRANCISCO, CA / ACCESSWIRE / September 24, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that Company management will host a conference call on Thursday, October...
► Artikel lesen
23.09.Jaguar Health, Inc.: Jaguar Health Comments on FDA's Decision to Set Packaging Limits for Anti-Diarrhea Medicine Loperamide (Imodium) to Encourage Safe Use431Mytesi® Novel Anti-Diarrheal Mechanism of Action Distinguished as Non-Opioid SAN FRANCISCO, CA / ACCESSWIRE / September 23, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") issued...
► Artikel lesen
20.09.Jaguar Health, Inc. - 8-K, Current Report-
19.09.Jaguar Health, Inc.: Jaguar Health to Present at Ladenburg Thalmann Healthcare Conference September 24 in New York215SAN FRANCISCO, CA / ACCESSWIRE / September 19, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that Lisa Conte, Jaguar's founder, president and CEO, will present...
► Artikel lesen
18.09.Jaguar Health, Inc.: Jaguar Health Filing for Second Indication of Exercise-Induced Diarrhea in Dogs Under MUMS for Crofelemer269Company's Legacy Animal Health Business Supports Focus on Human Health Benefits SAN FRANCISCO, CA / ACCESSWIRE / September 18, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") issued...
► Artikel lesen
16.09.Jaguar Health, Inc.: Jaguar Health's Mytesi Drug Product Now Approved for Sale in Puerto Rico186Puerto Rico Had the 7th Highest Cumulative Rate of HIV Infection in the Nation in 2016 SAN FRANCISCO, CA / ACCESSWIRE / September 16, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company")...
► Artikel lesen
13.09.5 Top Gainers In Healthcare Sector (SINT, JAGX, EVLO)3
09.09.Jaguar Health, Inc. - 8-K, Current Report2
09.09.Jaguar Health, Inc.: Jaguar Health Promotes Jonathan Wolin to Chief of Staff, Chief Compliance Officer & General Counsel287SAN FRANCISCO, CA / ACCESSWIRE / September 9, 2019 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that the Company has promoted Jonathan Wolin, an accomplished healthcare...
► Artikel lesen
Seite:  Weiter >>
99 Nachrichten in den letzten 12 Monaten

Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2